Postchemoembolisation Syndrome: Tumour Necrosis or Liver Injury?
Author Information
Author(s): Wigmore S J, Redhead D N, Thomson B N J, Currie E J, Parks R W, Madhavan K K, Garden O J
Primary Institution: University of Edinburgh, Royal Infirmary
Hypothesis
Does the postchemoembolisation syndrome represent injury to normal hepatocytes or tumour necrosis?
Conclusion
The study found that the postchemoembolisation syndrome may indicate liver cell damage rather than tumour necrosis.
Supporting Evidence
- The postchemoembolisation syndrome occurs in 40-85% of patients undergoing TACE.
- Elevation of transaminases was observed in 93% of patients after TACE.
- Patients with primary liver tumours and postchemoembolisation syndrome had poorer survival outcomes.
Takeaway
This study looked at whether a common side effect of a liver cancer treatment means the treatment is working or if it's hurting healthy liver cells instead.
Methodology
The study examined patients who underwent TACE for liver tumours, collecting data on their responses and survival over a minimum of 3 years.
Potential Biases
Potential bias due to the study's focus on a specific type of liver cancer.
Limitations
The study primarily included patients with primary hepatocellular carcinoma, which may limit the generalizability of the findings.
Participant Demographics
101 men and 44 women, median age 63 years, with 52% having hepatocellular carcinoma.
Statistical Information
P-Value
0.0076
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website